{"id":109789,"date":"2026-11-11T11:51:38","date_gmt":"2026-11-11T10:51:38","guid":{"rendered":"https:\/\/www.medipan.de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/"},"modified":"2026-11-19T11:44:35","modified_gmt":"2026-11-19T10:44:35","slug":"type-1-diabetes-autoantibody-screening-in-the-general-population","status":"publish","type":"post","link":"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/","title":{"rendered":"Screening auf Typ-1-Diabetes-Autoantik\u00f6rper in der Allgemeinbev\u00f6lkerung"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Ein internationaler Konsens aus dem Jahr 2026 empfiehlt, die Allgemeinbev\u00f6lkerung ab einem Alter von 2 bis 4 Jahren auf Inselautoantik\u00f6rper (IAbs) zu untersuchen. Die von 20 nationalen und internationalen Diabetes-Organisationen unterst\u00fctzte Leitlinie beschreibt einen strukturierten Ansatz zur Erkennung von Typ-1-Diabetes (T1D), bevor klinische Symptome auftreten. Das Screening zielt darauf ab, die Autoimmunerkrankung zu erkennen, solange die Glukoseregulierung noch normal oder nur teilweise beeintr\u00e4chtigt ist <sup data-fn=\"6bd0e39d-f7c8-4b1e-90c9-d55a66457eeb\" class=\"fn\"><a href=\"#6bd0e39d-f7c8-4b1e-90c9-d55a66457eeb\" id=\"6bd0e39d-f7c8-4b1e-90c9-d55a66457eeb-link\">1<\/a><\/sup>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Entstehung von Typ-1-Diabetes<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">T1D entwickelt sich in Stadien, die durch Inselautoimmunit\u00e4t und den Blutzuckerstatus definiert sind. Autoantik\u00f6rper gegen Insulin (IAA), GAD65 (Anti-GAD), Proteintyrosinphosphatase (Anti-IA2) und Zinktransporter 8 (Anti-ZnT8) sind die wichtigsten serologischen Marker. Ein einzelner best\u00e4tigter Autoantik\u00f6rper deutet auf ein erh\u00f6htes Risiko hin, bedeutet jedoch noch nicht, dass sich T1D im Fr\u00fchstadium befindet.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>T1D im Stadium 1 <\/strong>ist durch mindestens zwei best\u00e4tigte Insel-Autoantik\u00f6rper bei normaler Blutzuckerkontrolle gekennzeichnet;<\/li>\n\n\n\n<li><strong>T1D im Stadium 2 <\/strong>verbindet eine Inselautoimmunit\u00e4t, die in der Regel mehrere Autoantik\u00f6rper umfasst, mit einer nicht-diabetischen Dysglyk\u00e4mie;<\/li>\n\n\n\n<li><strong>T1D im Stadium 3<\/strong> ist durch eine Hyperglyk\u00e4mie gekennzeichnet, die die Standard-Diagnosekriterien f\u00fcr Diabetes erf\u00fcllt, mit oder ohne Symptome. Insel-Autoantik\u00f6rper sind in diesem Stadium m\u00f6glicherweise nicht mehr nachweisbar<sup data-fn=\"81b3f01d-9bf4-47b5-b20e-0d7de572b0e7\" class=\"fn\"><a href=\"#81b3f01d-9bf4-47b5-b20e-0d7de572b0e7\" id=\"81b3f01d-9bf4-47b5-b20e-0d7de572b0e7-link\">2<\/a><\/sup>.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/Typ-1-Diabetes_-Stadien-und-Marker-1024x576.png\" alt=\"\" class=\"wp-image-109798\" srcset=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/Typ-1-Diabetes_-Stadien-und-Marker-1024x576.png 1024w, https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/Typ-1-Diabetes_-Stadien-und-Marker-300x169.png 300w, https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/Typ-1-Diabetes_-Stadien-und-Marker-768x432.png 768w, https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/Typ-1-Diabetes_-Stadien-und-Marker-1536x864.png 1536w, https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/Typ-1-Diabetes_-Stadien-und-Marker.png 1672w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><sub>In Anlehnung an Insel RA et al. (2015). <em>Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, und der American Diabetes Association.<\/em> Die Abbildung wurde mithilfe von KI erstellt..<\/sub><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Warum Vorsorgeuntersuchungen \u00fcber die Familienanamnese hinausgehen sollten<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Die Beschr\u00e4nkung von Vorsorgeuntersuchungen auf Personen mit hohem Risiko, wie beispielsweise Angeh\u00f6rige von Menschen mit T1D, f\u00fchrt dazu, dass viele zuk\u00fcnftige F\u00e4lle unentdeckt bleiben, da die meisten Personen, die an Typ-1-Diabetes im Stadium 3 erkranken, keine famili\u00e4re Vorbelastung f\u00fcr diese Erkrankung aufweisen. Der Konsens empfiehlt daher, Vorsorgeuntersuchungen der allgemeinen Bev\u00f6lkerung anzubieten, sofern die Gesundheitspolitik und die Infrastruktur deren Umsetzung unterst\u00fctzen.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Der klinische Nutzen h\u00e4ngt davon ab, welche Ma\u00dfnahmen nach der Erkennung folgen. Die Erkennung von Typ-1-Diabetes im Fr\u00fchstadium erm\u00f6glicht Aufkl\u00e4rung \u00fcber Symptome, Stoffwechsel\u00fcberwachung und rechtzeitige Intervention, was zu weniger F\u00e4llen von diabetischer Ketoazidose bei der klinischen Diagnose und einem milderen Krankheitsverlauf f\u00fchrt. Eine fr\u00fchzeitige Erkennung kann zudem den Zugang zu krankheitsmodifizierenden Therapien oder klinischen Studien erleichtern.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><br>F\u00fcr eine umfassendere Betrachtung, wie eine fr\u00fchzeitigere Erkennung und neue Therapieans\u00e4tze die Versorgung von Typ-1-Diabetes ver\u00e4ndern k\u00f6nnten, lesen Sie unseren <a href=\"https:\/\/www.medipan.de\/de\/von-der-diagnose-zur-praevention-wie-sich-das-management-von-typ-1-diabetes-in-fuenf-jahren-veraendern-koennte\/?utm_source=chatgpt.com\">Artikel zu diesem Thema<\/a>.<\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Beginnen Sie mit Kindern im Vorschulalter und f\u00fchren Sie im Laufe der Kindheit Wiederholungsuntersuchungen durch<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Der empfohlene Untersuchungsplan beginnt im Alter von 2 bis 4 Jahren, gefolgt von Wiederholungsuntersuchungen im Alter von 6 bis 8 sowie 10 bis 15 Jahren, sofern die vorherigen Ergebnisse negativ waren. Kinder, die noch nie untersucht wurden, sollten so fr\u00fch wie m\u00f6glich in den Untersuchungsplan aufgenommen werden.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Wiederholungsuntersuchungen sind wichtig, da ein negatives Ergebnis lediglich den Antik\u00f6rperstatus zum Zeitpunkt der Probenentnahme widerspiegelt und eine sp\u00e4tere Entwicklung einer Inselautoimmunit\u00e4t nicht ausschlie\u00dft<sup data-fn=\"6e2ef7c0-50b4-48c1-941b-0ae05db49c43\" class=\"fn\"><a href=\"#6e2ef7c0-50b4-48c1-941b-0ae05db49c43\" id=\"6e2ef7c0-50b4-48c1-941b-0ae05db49c43-link\">3<\/a><\/sup>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">W\u00e4hlen Sie ein geeignetes Autoantik\u00f6rper-Panel aus<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Die vier Autoantik\u00f6rper-Spezifit\u00e4ten, die die Grundlage des Screenings bilden, sind IAA, Anti-GAD, Anti-IA2 und Anti-ZnT8. Der Konsens empfiehlt, dass beim Erstscreening mindestens drei dieser vier Marker nachgewiesen werden und dass bei Best\u00e4tigungstests alle vier Spezifit\u00e4ten unterschieden werden sollten. F\u00fcr das Screening der Allgemeinbev\u00f6lkerung empfiehlt der Konsens antigenspezifische Tests und beh\u00e4lt die ICA-Immunfluoreszenz f\u00fcr Forschungszwecke vor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bei der Testauswahl sollten Unterschiede hinsichtlich des prognostischen Werts und der altersabh\u00e4ngigen Pr\u00e4valenz von IAbs ber\u00fccksichtigt werden. So weist beispielsweise eine Anti-IA2-Positivit\u00e4t einen h\u00f6heren positiven pr\u00e4diktiven Wert (PPV) f\u00fcr das Fortschreiten zu Typ-1-Diabetes im Stadium 3 auf als die Positivit\u00e4t f\u00fcr andere Insel-Autoantik\u00f6rper<sup data-fn=\"1d6cf11e-137d-4b55-abca-8155ec8a5310\" class=\"fn\"><a href=\"#1d6cf11e-137d-4b55-abca-8155ec8a5310\" id=\"1d6cf11e-137d-4b55-abca-8155ec8a5310-link\">4<\/a><\/sup>. Der Einsatz von IAA und Anti-GAD bietet wahrscheinlich die h\u00f6chste Sensitivit\u00e4t f\u00fcr die Erkennung von Typ-1-Diabetes im Fr\u00fchstadium bei Kindern, allerdings werden IAA bei Erwachsenen seltener nachgewiesen als bei Kindern<sup data-fn=\"a7902a3a-6a10-498b-90b3-65ab83185808\" class=\"fn\"><a href=\"#a7902a3a-6a10-498b-90b3-65ab83185808\" id=\"a7902a3a-6a10-498b-90b3-65ab83185808-link\">5<\/a><\/sup>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">F\u00fcr Laboratorien bedeutet dies eine <strong>empfindliche Strategie<\/strong> f\u00fcr Erstuntersuchungen, erg\u00e4nzt durch spezifischere Best\u00e4tigungstests. Die Tests m\u00fcssen f\u00fcr den klinischen Einsatz validiert sein und einer angemessenen Qualit\u00e4tssicherung sowie einer externen Eignungspr\u00fcfung unterzogen werden.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Best\u00e4tigen Sie positive Ergebnisse, bevor Sie eine Diagnose stellen<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ein positives Screening-Ergebnis muss anhand einer zweiten Blutprobe best\u00e4tigt werden. Idealerweise sollte die Best\u00e4tigung mit einer anderen Testmethode erfolgen, da sich die Methoden hinsichtlich ihrer Anf\u00e4lligkeit f\u00fcr falsch-positive Signale unterscheiden k\u00f6nnen. F\u00fcr Best\u00e4tigungsmessungen sollte Serum oder Plasma aus ven\u00f6sem Blut verwendet werden. Der bevorzugte Ansatz nach der \u201e2er-Regel\u201c kombiniert mindestens zwei positive Autoantik\u00f6rper-Spezifit\u00e4ten, zwei Testmethoden und zwei aufeinanderfolgende Proben.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bei der Interpretation und Nachsorge sollten das Alter der betroffenen Person sowie der klinische Kontext ber\u00fccksichtigt werden. Personen mit best\u00e4tigten multiplen IAbs sollten zur metabolischen Stadieneinteilung und zur Erstellung eines strukturierten \u00dcberwachungsplans \u00fcberwiesen werden.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Die Forschung zur Inselautoimmunit\u00e4t erstreckt sich zunehmend auch auf nicht-europ\u00e4ische Bev\u00f6lkerungsgruppen, wie eine Studie an Menschen mit klinisch diagnostiziertem T1D in Ghana zeigt<sup data-fn=\"64648a34-6e5e-4d3c-93fa-c456704eb0ea\" class=\"fn\"><a href=\"#64648a34-6e5e-4d3c-93fa-c456704eb0ea\" id=\"64648a34-6e5e-4d3c-93fa-c456704eb0ea-link\">6<\/a><\/sup>. In \u00e4hnlicher Weise befassen sich auch andere Forschungsarbeiten mit gleichzeitig auftretenden Autoimmunerkrankungen, wie beispielsweise eine Studie \u00fcber junge Menschen, die sowohl an Typ-1-Diabetes als auch an Z\u00f6liakie leiden<sup data-fn=\"48def082-58f0-443a-b495-9bcac6627859\" class=\"fn\"><a href=\"#48def082-58f0-443a-b495-9bcac6627859\" id=\"48def082-58f0-443a-b495-9bcac6627859-link\">7<\/a><\/sup>.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<pre class=\"wp-block-verse\">Weitere Informationen zur serologischen Diagnostik der Z\u00f6liakie, einschlie\u00dflich der Bedeutung eines IgA-Mangels, finden Sie in unserem <a href=\"https:\/\/www.medipan.de\/de\/diagnostische-leitlinien-fuer-zoeliakie-umgang-mit-der-herausforderung-des-selektiven-iga-mangels\/?utm_source=chatgpt.com\">Artikel zur Z\u00f6liakie-Diagnostik<\/a>.<\/pre>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\">Das Screening in einen umfassenden Versorgungsweg integrieren<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Der Konsens bef\u00fcrwortet die Integration des Autoantik\u00f6rper-Screenings bei Kindern in die Vorsorge, verbunden mit einer zuverl\u00e4ssigen Best\u00e4tigung und einer kontinuierlichen Betreuung der identifizierten F\u00e4lle. Bei der Umsetzung m\u00fcssen die lokale Krankheitspr\u00e4valenz, die Laborkapazit\u00e4ten und der Zugang zu fach\u00e4rztlicher Nachsorge ber\u00fccksichtigt werden. F\u00fcr die Labordienstleistungen steht ein koordinierter Versorgungsweg im Vordergrund, der den pr\u00e4zisen Antik\u00f6rpernachweis mit einer klaren klinischen Reaktion verkn\u00fcpft. Als erstes Land hat Italien einen gesetzlichen Rahmen f\u00fcr ein nationales p\u00e4diatrisches Screening-Programm f\u00fcr Typ-1-Diabetes und Z\u00f6liakie geschaffen und damit die Bedeutung der Fr\u00fcherkennung f\u00fcr die \u00f6ffentliche Gesundheit unterstrichen<sup data-fn=\"b21652bc-591c-4106-adc3-e0a09c07a250\" class=\"fn\"><a href=\"#b21652bc-591c-4106-adc3-e0a09c07a250\" id=\"b21652bc-591c-4106-adc3-e0a09c07a250-link\">8<\/a><\/sup>.<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"606\" src=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/image-edited-1024x606.png\" alt=\"\" class=\"wp-image-109786\" srcset=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/image-edited-1024x606.png 1024w, https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/image-edited-300x178.png 300w, https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/image-edited-768x455.png 768w, https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/image-edited-1536x909.png 1536w, https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/image-edited.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">\u00c4hnliche Produkte<\/h2>\n\n\n<div class=\"lh-block-lh-bibliography lh-bibliography-block wp-block-lh-bibliography\">\n\t<ul class=\"lh-bibliography-block--citations\">\n\t\t\t<\/ul>\n<\/div>\n\n\n<div class=\"block block-product-references\">\n\n\t\t\t<h2 class=\"product-references__heading\">Quantitative Bestimmung von Antik\u00f6rpern gegen die Glutamins\u00e4ure-Decarboxylase (GAD65)<\/h2>\n\t\n\t<ul class=\"product-references__list\">\n\t\t\t\t\t<li class=\"product-references__item\">\n\t\t\t\t<a class=\"product-references__link\" href=\"https:\/\/www.medipan.de\/de\/products\/3507-medizym-anti-gad-m\/\">\n\n\t\t\t\t\t<div class=\"product-references__body\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__title\">\n\t\t\t\t\t\t\t3507 &#8211; Medizym<sup>\u00ae<\/sup> anti-GAD M\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__description\">\n\t\t\t\t\t\t\t\tEnzymimmunoassay zur quantitativen Bestimmung von Antik\u00f6rpern gegen Glutamins\u00e4uredecarboxylase (GAD65)\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"product-references__arrow\" aria-hidden=\"true\">\n\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"13.19\" height=\"12.78\" viewBox=\"0 0 13.19 12.78\" aria-hidden=\"true\" focusable=\"false\">\n<path d=\"M1615.16,4359.93h-11.87a0.588,0.588,0,0,0,0,1.16h11.87A0.588,0.588,0,0,0,1615.16,4359.93Zm0.45,0.17-4.82-5.69a0.454,0.454,0,0,0-.7,0,0.661,0.661,0,0,0,0,.82l4.47,5.28-4.47,5.27a0.661,0.661,0,0,0,0,.82,0.439,0.439,0,0,0,.35.17,0.453,0.453,0,0,0,.35-0.17l4.82-5.68A0.661,0.661,0,0,0,1615.61,4360.1Z\" transform=\"translate(-1602.685 -4354.125)\" fill=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke-width=\"0.25\"\/>\n<\/svg>\t\t\t\t\t<\/div>\n\n\t\t\t\t<\/a>\n\t\t\t<\/li>\n\t\t\t\t\t<li class=\"product-references__item\">\n\t\t\t\t<a class=\"product-references__link\" href=\"https:\/\/www.medipan.de\/de\/products\/2070-2071-centak-anti-gad65-m\/\">\n\n\t\t\t\t\t<div class=\"product-references__body\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__title\">\n\t\t\t\t\t\t\t2070, 2071 &#8211; CentAK<sup>\u00ae<\/sup> anti-GAD<sub>65<\/sub> M\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__description\">\n\t\t\t\t\t\t\t\tRadioimmunoassay zur quantitativen Bestimmung von Antik\u00f6rpern gegen Glutamins\u00e4uredecarboxylase (GAD65)\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"product-references__arrow\" aria-hidden=\"true\">\n\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"13.19\" height=\"12.78\" viewBox=\"0 0 13.19 12.78\" aria-hidden=\"true\" focusable=\"false\">\n<path d=\"M1615.16,4359.93h-11.87a0.588,0.588,0,0,0,0,1.16h11.87A0.588,0.588,0,0,0,1615.16,4359.93Zm0.45,0.17-4.82-5.69a0.454,0.454,0,0,0-.7,0,0.661,0.661,0,0,0,0,.82l4.47,5.28-4.47,5.27a0.661,0.661,0,0,0,0,.82,0.439,0.439,0,0,0,.35.17,0.453,0.453,0,0,0,.35-0.17l4.82-5.68A0.661,0.661,0,0,0,1615.61,4360.1Z\" transform=\"translate(-1602.685 -4354.125)\" fill=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke-width=\"0.25\"\/>\n<\/svg>\t\t\t\t\t<\/div>\n\n\t\t\t\t<\/a>\n\t\t\t<\/li>\n\t\t\t<\/ul>\n\n<\/div>\n\n\n<div class=\"block block-product-references\">\n\n\t\t\t<h2 class=\"product-references__heading\">Quantitative determination of antibodies against Protein Tyrosine Phosphatase (IA2) <\/h2>\n\t\n\t<ul class=\"product-references__list\">\n\t\t\t\t\t<li class=\"product-references__item\">\n\t\t\t\t<a class=\"product-references__link\" href=\"https:\/\/www.medipan.de\/de\/products\/2050-2150-centak-anti-ia2-m\/\">\n\n\t\t\t\t\t<div class=\"product-references__body\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__title\">\n\t\t\t\t\t\t\t2050, 2150 &#8211; CentAK<sup>\u00ae<\/sup> anti-IA<sub>2<\/sub> M\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__description\">\n\t\t\t\t\t\t\t\tRadioimmunoassay zur quantitativen Bestimmung von Antik\u00f6rpern gegen Protein-Tyrosin-Phosphatase (IA2)\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"product-references__arrow\" aria-hidden=\"true\">\n\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"13.19\" height=\"12.78\" viewBox=\"0 0 13.19 12.78\" aria-hidden=\"true\" focusable=\"false\">\n<path d=\"M1615.16,4359.93h-11.87a0.588,0.588,0,0,0,0,1.16h11.87A0.588,0.588,0,0,0,1615.16,4359.93Zm0.45,0.17-4.82-5.69a0.454,0.454,0,0,0-.7,0,0.661,0.661,0,0,0,0,.82l4.47,5.28-4.47,5.27a0.661,0.661,0,0,0,0,.82,0.439,0.439,0,0,0,.35.17,0.453,0.453,0,0,0,.35-0.17l4.82-5.68A0.661,0.661,0,0,0,1615.61,4360.1Z\" transform=\"translate(-1602.685 -4354.125)\" fill=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke-width=\"0.25\"\/>\n<\/svg>\t\t\t\t\t<\/div>\n\n\t\t\t\t<\/a>\n\t\t\t<\/li>\n\t\t\t\t\t<li class=\"product-references__item\">\n\t\t\t\t<a class=\"product-references__link\" href=\"https:\/\/www.medipan.de\/de\/products\/3506-medizym-anti-ia2-m\/\">\n\n\t\t\t\t\t<div class=\"product-references__body\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__title\">\n\t\t\t\t\t\t\t3506 &#8211; Medizym<sup>\u00ae<\/sup> anti-IA2 M\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__description\">\n\t\t\t\t\t\t\t\tEnzymimmunoassay zur quantitativen Bestimmung von Antik\u00f6rpern gegen Protein-Tyrosin-Phosphatase (IA2)\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"product-references__arrow\" aria-hidden=\"true\">\n\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"13.19\" height=\"12.78\" viewBox=\"0 0 13.19 12.78\" aria-hidden=\"true\" focusable=\"false\">\n<path d=\"M1615.16,4359.93h-11.87a0.588,0.588,0,0,0,0,1.16h11.87A0.588,0.588,0,0,0,1615.16,4359.93Zm0.45,0.17-4.82-5.69a0.454,0.454,0,0,0-.7,0,0.661,0.661,0,0,0,0,.82l4.47,5.28-4.47,5.27a0.661,0.661,0,0,0,0,.82,0.439,0.439,0,0,0,.35.17,0.453,0.453,0,0,0,.35-0.17l4.82-5.68A0.661,0.661,0,0,0,1615.61,4360.1Z\" transform=\"translate(-1602.685 -4354.125)\" fill=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke-width=\"0.25\"\/>\n<\/svg>\t\t\t\t\t<\/div>\n\n\t\t\t\t<\/a>\n\t\t\t<\/li>\n\t\t\t<\/ul>\n\n<\/div>\n\n\n<div class=\"block block-product-references\">\n\n\t\t\t<h2 class=\"product-references__heading\">Quantitative Bestimmung von Antik\u00f6rpern gegen Insulin (IAA)<\/h2>\n\t\n\t<ul class=\"product-references__list\">\n\t\t\t\t\t<li class=\"product-references__item\">\n\t\t\t\t<a class=\"product-references__link\" href=\"https:\/\/www.medipan.de\/de\/products\/3806-medizym-iaa\/\">\n\n\t\t\t\t\t<div class=\"product-references__body\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__title\">\n\t\t\t\t\t\t\t3806 &#8211; Medizym<sup>\u00ae<\/sup> IAA\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__description\">\n\t\t\t\t\t\t\t\tEnzymimmunoassay zur quantitativen Bestimmung von IgG Antik\u00f6rpern gegen Insulin\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"product-references__arrow\" aria-hidden=\"true\">\n\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"13.19\" height=\"12.78\" viewBox=\"0 0 13.19 12.78\" aria-hidden=\"true\" focusable=\"false\">\n<path d=\"M1615.16,4359.93h-11.87a0.588,0.588,0,0,0,0,1.16h11.87A0.588,0.588,0,0,0,1615.16,4359.93Zm0.45,0.17-4.82-5.69a0.454,0.454,0,0,0-.7,0,0.661,0.661,0,0,0,0,.82l4.47,5.28-4.47,5.27a0.661,0.661,0,0,0,0,.82,0.439,0.439,0,0,0,.35.17,0.453,0.453,0,0,0,.35-0.17l4.82-5.68A0.661,0.661,0,0,0,1615.61,4360.1Z\" transform=\"translate(-1602.685 -4354.125)\" fill=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke-width=\"0.25\"\/>\n<\/svg>\t\t\t\t\t<\/div>\n\n\t\t\t\t<\/a>\n\t\t\t<\/li>\n\t\t\t\t\t<li class=\"product-references__item\">\n\t\t\t\t<a class=\"product-references__link\" href=\"https:\/\/www.medipan.de\/de\/products\/2035-centak-iaa-m\/\">\n\n\t\t\t\t\t<div class=\"product-references__body\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__title\">\n\t\t\t\t\t\t\t2035 &#8211; CentAK<sup>\u00ae<\/sup> IAA M\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__description\">\n\t\t\t\t\t\t\t\tRadioimmunoassay zur quantitativen Bestimmung von Antik\u00f6rpern gegen Insulin (IAA)\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"product-references__arrow\" aria-hidden=\"true\">\n\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"13.19\" height=\"12.78\" viewBox=\"0 0 13.19 12.78\" aria-hidden=\"true\" focusable=\"false\">\n<path d=\"M1615.16,4359.93h-11.87a0.588,0.588,0,0,0,0,1.16h11.87A0.588,0.588,0,0,0,1615.16,4359.93Zm0.45,0.17-4.82-5.69a0.454,0.454,0,0,0-.7,0,0.661,0.661,0,0,0,0,.82l4.47,5.28-4.47,5.27a0.661,0.661,0,0,0,0,.82,0.439,0.439,0,0,0,.35.17,0.453,0.453,0,0,0,.35-0.17l4.82-5.68A0.661,0.661,0,0,0,1615.61,4360.1Z\" transform=\"translate(-1602.685 -4354.125)\" fill=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke-width=\"0.25\"\/>\n<\/svg>\t\t\t\t\t<\/div>\n\n\t\t\t\t<\/a>\n\t\t\t<\/li>\n\t\t\t<\/ul>\n\n<\/div>\n\n\n<div class=\"block block-product-references\">\n\n\t\t\t<h2 class=\"product-references__heading\">Immunofluorescence Determination of IgG antibodies against islet cells (ICA)<\/h2>\n\t\n\t<ul class=\"product-references__list\">\n\t\t\t\t\t<li class=\"product-references__item\">\n\t\t\t\t<a class=\"product-references__link\" href=\"https:\/\/www.medipan.de\/de\/products\/4129-aklides-ica\/\">\n\n\t\t\t\t\t<div class=\"product-references__body\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__title\">\n\t\t\t\t\t\t\t4129 &#8211; AKLIDES<sup>\u00ae<\/sup> ICA\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__description\">\n\t\t\t\t\t\t\t\tImmunfluoreszenz-Assay (IFA) zur Bestimmung von IgG-Antik\u00f6rpern gegen Inselzellenantigene (ICA) in einem automatisierten System\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"product-references__arrow\" aria-hidden=\"true\">\n\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"13.19\" height=\"12.78\" viewBox=\"0 0 13.19 12.78\" aria-hidden=\"true\" focusable=\"false\">\n<path d=\"M1615.16,4359.93h-11.87a0.588,0.588,0,0,0,0,1.16h11.87A0.588,0.588,0,0,0,1615.16,4359.93Zm0.45,0.17-4.82-5.69a0.454,0.454,0,0,0-.7,0,0.661,0.661,0,0,0,0,.82l4.47,5.28-4.47,5.27a0.661,0.661,0,0,0,0,.82,0.439,0.439,0,0,0,.35.17,0.453,0.453,0,0,0,.35-0.17l4.82-5.68A0.661,0.661,0,0,0,1615.61,4360.1Z\" transform=\"translate(-1602.685 -4354.125)\" fill=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke-width=\"0.25\"\/>\n<\/svg>\t\t\t\t\t<\/div>\n\n\t\t\t\t<\/a>\n\t\t\t<\/li>\n\t\t\t\t\t<li class=\"product-references__item\">\n\t\t\t\t<a class=\"product-references__link\" href=\"https:\/\/www.medipan.de\/de\/products\/85848-ica-ifa\/\">\n\n\t\t\t\t\t<div class=\"product-references__body\">\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__title\">\n\t\t\t\t\t\t\t85848 &#8211; ICA IFA\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"product-references__description\">\n\t\t\t\t\t\t\t\tImmunfluoreszenzassay (IFA) zur Bestimmung von IgG Antik\u00f6rpern gegen Inselzellen (ICA)\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"product-references__arrow\" aria-hidden=\"true\">\n\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"13.19\" height=\"12.78\" viewBox=\"0 0 13.19 12.78\" aria-hidden=\"true\" focusable=\"false\">\n<path d=\"M1615.16,4359.93h-11.87a0.588,0.588,0,0,0,0,1.16h11.87A0.588,0.588,0,0,0,1615.16,4359.93Zm0.45,0.17-4.82-5.69a0.454,0.454,0,0,0-.7,0,0.661,0.661,0,0,0,0,.82l4.47,5.28-4.47,5.27a0.661,0.661,0,0,0,0,.82,0.439,0.439,0,0,0,.35.17,0.453,0.453,0,0,0,.35-0.17l4.82-5.68A0.661,0.661,0,0,0,1615.61,4360.1Z\" transform=\"translate(-1602.685 -4354.125)\" fill=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke=\"var(--wp--preset--color--blue,#4bb2fd)\" stroke-width=\"0.25\"\/>\n<\/svg>\t\t\t\t\t<\/div>\n\n\t\t\t\t<\/a>\n\t\t\t<\/li>\n\t\t\t<\/ul>\n\n<\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Referenzen<\/h2>\n\n\n<ol class=\"wp-block-footnotes\"><li id=\"6bd0e39d-f7c8-4b1e-90c9-d55a66457eeb\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42720753\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ziegler <em>et al.<\/em>, 2026, International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes: a nominal group technique process<\/a> <a href=\"#6bd0e39d-f7c8-4b1e-90c9-d55a66457eeb-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 1 navigieren\">\u21a9\ufe0e<\/a><\/li><li id=\"81b3f01d-9bf4-47b5-b20e-0d7de572b0e7\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12690183\/\" target=\"_blank\" rel=\"noreferrer noopener\">American Diabetes Association Professional Practice Committee for Diabetes., 2026, Diagnosis and Classification of Diabetes: Standards of Care in Diabetes\u20142026<\/a> <a href=\"#81b3f01d-9bf4-47b5-b20e-0d7de572b0e7-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 2 navigieren\">\u21a9\ufe0e<\/a><\/li><li id=\"6e2ef7c0-50b4-48c1-941b-0ae05db49c43\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166139\/\" target=\"_blank\" rel=\"noreferrer noopener\">Winkler et al., 2026, Screening Children for Early-Stage Type 1 Diabetes<\/a> <a href=\"#6e2ef7c0-50b4-48c1-941b-0ae05db49c43-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 3 navigieren\">\u21a9\ufe0e<\/a><\/li><li id=\"1d6cf11e-137d-4b55-abca-8155ec8a5310\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40016443\/\" target=\"_blank\" rel=\"noreferrer noopener\">Sims <em>et al.<\/em>, 2025, IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes<\/a> <a href=\"#1d6cf11e-137d-4b55-abca-8155ec8a5310-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 4 navigieren\">\u21a9\ufe0e<\/a><\/li><li id=\"a7902a3a-6a10-498b-90b3-65ab83185808\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40496897\/\" target=\"_blank\" rel=\"noreferrer noopener\">Pauley <em>et al.<\/em>, 2025,<sup>\u00a0<\/sup>Prevalence of Islet Autoantibodies in Adults Without Diabetes<\/a> <a href=\"#a7902a3a-6a10-498b-90b3-65ab83185808-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 5 navigieren\">\u21a9\ufe0e<\/a><\/li><li id=\"64648a34-6e5e-4d3c-93fa-c456704eb0ea\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41175199\/\" target=\"_blank\" rel=\"noreferrer noopener\">Aniagyei <em>et al.<\/em>, 2026, Heterogeneity in clinically diagnosed type 1 diabetes: characterising a unique cohort with maintained C-peptide secretion in Ghana<\/a> <a href=\"#64648a34-6e5e-4d3c-93fa-c456704eb0ea-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 6 navigieren\">\u21a9\ufe0e<\/a><\/li><li id=\"48def082-58f0-443a-b495-9bcac6627859\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41186271\/\">Di Candia <em>et al.<\/em>, 2026, Glucometabolic Control and Anti-Transglutaminase Antibodies at Celiac Disease Onset in Type 1 Diabetes Youth<\/a> <a href=\"#48def082-58f0-443a-b495-9bcac6627859-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 7 navigieren\">\u21a9\ufe0e<\/a><\/li><li id=\"b21652bc-591c-4106-adc3-e0a09c07a250\"><a href=\"https:\/\/www.gazzettaufficiale.it\/eli\/id\/2023\/09\/27\/23G00140\/sg\" target=\"_blank\" rel=\"noreferrer noopener\">Repubblica Italiana, 2023, Law 15 September 2023 n. 130, Disposizioni concernenti la definizione di un programma diagnostico per l\u2019individuazione del diabete di tipo 1 e della celiachia nella popolazione pediatrica<\/a> [in Italian] <a href=\"#b21652bc-591c-4106-adc3-e0a09c07a250-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 8 navigieren\">\u21a9\ufe0e<\/a><\/li><\/ol>\n\n<div class=\"wp-block-post-author-name\">Dr. Stefano Frasca<\/div>\n\n<div class=\"wp-block-post-date\"><time datetime=\"2026-11-11T11:51:38+01:00\">11\/11\/2026<\/time><\/div>\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ein internationaler Konsens aus dem Jahr 2026 empfiehlt, die Allgemeinbev\u00f6lkerung ab einem Alter von 2 bis 4 Jahren auf Inselautoantik\u00f6rper (IAbs) zu untersuchen. Die von 20 nationalen und internationalen Diabetes-Organisationen unterst\u00fctzte Leitlinie beschreibt einen strukturierten Ansatz zur Erkennung von Typ-1-Diabetes (T1D), bevor klinische Symptome auftreten. Das Screening zielt darauf ab, die Autoimmunerkrankung zu erkennen, solange [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":109791,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"[{\"content\":\"<a href=\\\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42720753\/\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">Ziegler <em>et al.<\/em>, 2026, International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes: a nominal group technique process<\/a>\",\"id\":\"6bd0e39d-f7c8-4b1e-90c9-d55a66457eeb\"},{\"content\":\"<a href=\\\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12690183\/\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">American Diabetes Association Professional Practice Committee for Diabetes., 2026, Diagnosis and Classification of Diabetes: Standards of Care in Diabetes\u20142026<\/a>\",\"id\":\"81b3f01d-9bf4-47b5-b20e-0d7de572b0e7\"},{\"content\":\"<a href=\\\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42166139\/\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">Winkler et al., 2026, Screening Children for Early-Stage Type 1 Diabetes<\/a>\",\"id\":\"6e2ef7c0-50b4-48c1-941b-0ae05db49c43\"},{\"content\":\"<a href=\\\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40016443\/\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">Sims <em>et al.<\/em>, 2025, IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes<\/a>\",\"id\":\"1d6cf11e-137d-4b55-abca-8155ec8a5310\"},{\"content\":\"<a href=\\\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40496897\/\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">Pauley <em>et al.<\/em>, 2025,<sup>\u00a0<\/sup>Prevalence of Islet Autoantibodies in Adults Without Diabetes<\/a>\",\"id\":\"a7902a3a-6a10-498b-90b3-65ab83185808\"},{\"content\":\"<a href=\\\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41175199\/\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">Aniagyei <em>et al.<\/em>, 2026, Heterogeneity in clinically diagnosed type 1 diabetes: characterising a unique cohort with maintained C-peptide secretion in Ghana<\/a>\",\"id\":\"64648a34-6e5e-4d3c-93fa-c456704eb0ea\"},{\"content\":\"<a href=\\\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41186271\/\\\">Di Candia <em>et al.<\/em>, 2026, Glucometabolic Control and Anti-Transglutaminase Antibodies at Celiac Disease Onset in Type 1 Diabetes Youth<\/a>\",\"id\":\"48def082-58f0-443a-b495-9bcac6627859\"},{\"content\":\"<a href=\\\"https:\/\/www.gazzettaufficiale.it\/eli\/id\/2023\/09\/27\/23G00140\/sg\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">Repubblica Italiana, 2023, Law 15 September 2023 n. 130, Disposizioni concernenti la definizione di un programma diagnostico per l\u2019individuazione del diabete di tipo 1 e della celiachia nella popolazione pediatrica<\/a> [in Italian]\",\"id\":\"b21652bc-591c-4106-adc3-e0a09c07a250\"}]"},"categories":[177],"tags":[],"class_list":["post-109789","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-products-news-de"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Type 1 Diabetes Autoantibody (T1D) Screening in Children<\/title>\n<meta name=\"description\" content=\"2026 consensus on type 1 diabetes autoantibody screening: recommended ages, antibody panels, confirmation, and clinical follow-up.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Type 1 Diabetes Autoantibody (T1D) Screening in Children\" \/>\n<meta property=\"og:description\" content=\"2026 consensus on type 1 diabetes autoantibody screening: recommended ages, antibody panels, confirmation, and clinical follow-up.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/\" \/>\n<meta property=\"og:site_name\" content=\"Medipan &amp; GA Generic Assays\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/people\/Medipan-GA-Generic-Assays\/pfbid02ULuoTqAH3VaVSiKK1yK6und3uDLDWT5sPtqVXyQHcW1QBfBX1ywC47X62DBGZgril\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-11T10:51:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-19T10:44:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/Freundlicher-Blutabnahmetermin-im-Labor-1024x576.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Dr. Stefano Frasca\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Stefano Frasca\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"6\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/type-1-diabetes-autoantibody-screening-in-the-general-population\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/type-1-diabetes-autoantibody-screening-in-the-general-population\\\/\"},\"author\":{\"name\":\"Dr. Stefano Frasca\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#\\\/schema\\\/person\\\/79bd5fbc4d559d6bf0daa2d30d420904\"},\"headline\":\"Screening auf Typ-1-Diabetes-Autoantik\u00f6rper in der Allgemeinbev\u00f6lkerung\",\"datePublished\":\"2026-11-11T10:51:38+00:00\",\"dateModified\":\"2026-11-19T10:44:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/type-1-diabetes-autoantibody-screening-in-the-general-population\\\/\"},\"wordCount\":988,\"publisher\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/type-1-diabetes-autoantibody-screening-in-the-general-population\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Freundlicher-Blutabnahmetermin-im-Labor.png\",\"articleSection\":[\"Produktneuigkeiten\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/type-1-diabetes-autoantibody-screening-in-the-general-population\\\/\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/type-1-diabetes-autoantibody-screening-in-the-general-population\\\/\",\"name\":\"Type 1 Diabetes Autoantibody (T1D) Screening in Children\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/type-1-diabetes-autoantibody-screening-in-the-general-population\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/type-1-diabetes-autoantibody-screening-in-the-general-population\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Freundlicher-Blutabnahmetermin-im-Labor.png\",\"datePublished\":\"2026-11-11T10:51:38+00:00\",\"dateModified\":\"2026-11-19T10:44:35+00:00\",\"description\":\"2026 consensus on type 1 diabetes autoantibody screening: recommended ages, antibody panels, confirmation, and clinical follow-up.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/type-1-diabetes-autoantibody-screening-in-the-general-population\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.medipan.de\\\/de\\\/type-1-diabetes-autoantibody-screening-in-the-general-population\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/type-1-diabetes-autoantibody-screening-in-the-general-population\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Freundlicher-Blutabnahmetermin-im-Labor.png\",\"contentUrl\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Freundlicher-Blutabnahmetermin-im-Labor.png\",\"width\":1672,\"height\":941},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/type-1-diabetes-autoantibody-screening-in-the-general-population\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Screening auf Typ-1-Diabetes-Autoantik\u00f6rper in der Allgemeinbev\u00f6lkerung\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/\",\"name\":\"Medipan.de\",\"description\":\"Your reliable partner in autoimmune diagnostics\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#organization\",\"name\":\"Medipan GmbH & GA Generic Assays GmbH\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2021\\\/01\\\/logo_transparent.png\",\"contentUrl\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2021\\\/01\\\/logo_transparent.png\",\"width\":108,\"height\":49,\"caption\":\"Medipan GmbH & GA Generic Assays GmbH\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/people\\\/Medipan-GA-Generic-Assays\\\/pfbid02ULuoTqAH3VaVSiKK1yK6und3uDLDWT5sPtqVXyQHcW1QBfBX1ywC47X62DBGZgril\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/medipan-generic-assays-gmbh\\\/?originalSubdomain=de\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCFTKVg_v7n57CG7i9rPv-NQ\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#\\\/schema\\\/person\\\/79bd5fbc4d559d6bf0daa2d30d420904\",\"name\":\"Dr. Stefano Frasca\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g\",\"caption\":\"Dr. Stefano Frasca\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Type 1 Diabetes Autoantibody (T1D) Screening in Children","description":"2026 consensus on type 1 diabetes autoantibody screening: recommended ages, antibody panels, confirmation, and clinical follow-up.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/","og_locale":"de_DE","og_type":"article","og_title":"Type 1 Diabetes Autoantibody (T1D) Screening in Children","og_description":"2026 consensus on type 1 diabetes autoantibody screening: recommended ages, antibody panels, confirmation, and clinical follow-up.","og_url":"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/","og_site_name":"Medipan &amp; GA Generic Assays","article_publisher":"https:\/\/www.facebook.com\/people\/Medipan-GA-Generic-Assays\/pfbid02ULuoTqAH3VaVSiKK1yK6und3uDLDWT5sPtqVXyQHcW1QBfBX1ywC47X62DBGZgril\/","article_published_time":"2026-11-11T10:51:38+00:00","article_modified_time":"2026-11-19T10:44:35+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/Freundlicher-Blutabnahmetermin-im-Labor-1024x576.png","type":"image\/png"}],"author":"Dr. Stefano Frasca","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"Dr. Stefano Frasca","Gesch\u00e4tzte Lesezeit":"6\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/#article","isPartOf":{"@id":"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/"},"author":{"name":"Dr. Stefano Frasca","@id":"https:\/\/www.medipan.de\/de\/#\/schema\/person\/79bd5fbc4d559d6bf0daa2d30d420904"},"headline":"Screening auf Typ-1-Diabetes-Autoantik\u00f6rper in der Allgemeinbev\u00f6lkerung","datePublished":"2026-11-11T10:51:38+00:00","dateModified":"2026-11-19T10:44:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/"},"wordCount":988,"publisher":{"@id":"https:\/\/www.medipan.de\/de\/#organization"},"image":{"@id":"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/#primaryimage"},"thumbnailUrl":"https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/Freundlicher-Blutabnahmetermin-im-Labor.png","articleSection":["Produktneuigkeiten"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/","url":"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/","name":"Type 1 Diabetes Autoantibody (T1D) Screening in Children","isPartOf":{"@id":"https:\/\/www.medipan.de\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/#primaryimage"},"image":{"@id":"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/#primaryimage"},"thumbnailUrl":"https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/Freundlicher-Blutabnahmetermin-im-Labor.png","datePublished":"2026-11-11T10:51:38+00:00","dateModified":"2026-11-19T10:44:35+00:00","description":"2026 consensus on type 1 diabetes autoantibody screening: recommended ages, antibody panels, confirmation, and clinical follow-up.","breadcrumb":{"@id":"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/#primaryimage","url":"https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/Freundlicher-Blutabnahmetermin-im-Labor.png","contentUrl":"https:\/\/www.medipan.de\/wp-content\/uploads\/2026\/11\/Freundlicher-Blutabnahmetermin-im-Labor.png","width":1672,"height":941},{"@type":"BreadcrumbList","@id":"https:\/\/www.medipan.de\/de\/type-1-diabetes-autoantibody-screening-in-the-general-population\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.medipan.de\/de\/"},{"@type":"ListItem","position":2,"name":"Screening auf Typ-1-Diabetes-Autoantik\u00f6rper in der Allgemeinbev\u00f6lkerung"}]},{"@type":"WebSite","@id":"https:\/\/www.medipan.de\/de\/#website","url":"https:\/\/www.medipan.de\/de\/","name":"Medipan.de","description":"Your reliable partner in autoimmune diagnostics","publisher":{"@id":"https:\/\/www.medipan.de\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.medipan.de\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.medipan.de\/de\/#organization","name":"Medipan GmbH & GA Generic Assays GmbH","url":"https:\/\/www.medipan.de\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.medipan.de\/de\/#\/schema\/logo\/image\/","url":"https:\/\/www.medipan.de\/wp-content\/uploads\/2021\/01\/logo_transparent.png","contentUrl":"https:\/\/www.medipan.de\/wp-content\/uploads\/2021\/01\/logo_transparent.png","width":108,"height":49,"caption":"Medipan GmbH & GA Generic Assays GmbH"},"image":{"@id":"https:\/\/www.medipan.de\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/people\/Medipan-GA-Generic-Assays\/pfbid02ULuoTqAH3VaVSiKK1yK6und3uDLDWT5sPtqVXyQHcW1QBfBX1ywC47X62DBGZgril\/","https:\/\/www.linkedin.com\/company\/medipan-generic-assays-gmbh\/?originalSubdomain=de","https:\/\/www.youtube.com\/channel\/UCFTKVg_v7n57CG7i9rPv-NQ"]},{"@type":"Person","@id":"https:\/\/www.medipan.de\/de\/#\/schema\/person\/79bd5fbc4d559d6bf0daa2d30d420904","name":"Dr. Stefano Frasca","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g","caption":"Dr. Stefano Frasca"}}]}},"_links":{"self":[{"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/posts\/109789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/comments?post=109789"}],"version-history":[{"count":5,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/posts\/109789\/revisions"}],"predecessor-version":[{"id":109808,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/posts\/109789\/revisions\/109808"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/media\/109791"}],"wp:attachment":[{"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/media?parent=109789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/categories?post=109789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/tags?post=109789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}